INTERNATIONALLY-RENOWNED China National Pharmaceutical Group Co Ltd, Sinopharm, welcomed a group of journalists from the Asia-Pacific region for a visit to its headquarters in Beijing on Thursday 3 July.
The Chinese State-Owned Enterprise (SOE) is a global leader in the healthcare sector due to its “scale, performance and comprehensive strength.”
“Sinopharm has actively participated in the global mainstream pharmaceutical market, with overseas networks covering five continents and international business throughout the world.
“Sinopharm builds close cooperative relationships with more than 100 world-renowned suppliers of medicine, medical devices and health products, dealing with over 195 countries, regions and organizations,” a company official highlighted.
International COVID-19 Response
Since the outbreak of COVID-19, Sinopharm diligently fulfilled its role as the national team, main force and pillar of central enterprises in the fight against the global pandemic in line with the important instructions and directives of the Communist Party of China (CPC) General Secretary, President Xi Jinping.
In compliance with the requirements of the State-Owned Assets Supervision Commission of the State Council of China, Sinopharm has undertaken the critical task of providing foreign aid and exporting anti-pandemic supplies.
“Sinopharm has shipped over 4 billion pieces of medical protective equipment to 173 countries and regions, and exported and donated Sinopharm COVID-19 vaccines to 120 countries, regions and international organizations, covering populations in 196 countries.
“Sinopharm has been recognized with the honor of being named a National Advanced Collective in the Fight Against COVID-19,” the Sinopharm official further highlighted.
Industrial Chain Ownership Status
Sinopharm owns a complete industrial chain covering research and development, manufacturing logistics and distribution, retail chains, healthcare, engineering technology, exhibitions and events, international business and financial services.
Its Nutrition and Health business implements the “Healthy China” strategy based on the advantages of international trade, fully integrating the SOE’s business advantages in the whole life cycle, full service, whole industry chain and whole ecosystem in the field of medicine, medical treatment and health.
“Through propriety brands and exclusive partnerships with Japanese, Korean, European and American manufacturers, we distribute over 200 renowned health brands comprising 1,000+ SKUs (Stock Keeping Units) worldwide,” the official said.
Cutting-Edge Biotechnology Development
Focusing on the international pharmaceutical and health sectors, Sinopharm has actively strategized to invest in strategic emerging industries and future health-related sectors and fostered the development of new quality productive forces, which led to the establishment of Sinopharm Seragon, Sinopharm-Microcyto and Sinopharm-Elekta (Beijing) Medical Technology CO., LTD.
Sinopharm Seragon is a joint venture at the forefront of global aging intervention technologies, while Sinopharm-Microcyto is a joint venture specializing in cutting-edge biomanufacturing of allulose (psicose). Sinopharm-Elekta (Beijing) Medical Technology CO., LTD is the first state-owned international medical equipment joint venture in radiotherapy.
“We operate for biosynthesis laboratories and were granted five new national patents in 2023, which demonstrates our growing R&D capabilities,” the official said.
Traditional Chinese Medicine
Sinopharm has established the world’s largest cluster of the modern Traditional Chinese Medicine (TCM) industry, with nearly 60 production enterprises such as China Traditional Medicine Holdings Co., Ltd and Chongqing Taiji Industry (Group) Co., Ltd.
It has formed a complete industrial chain covering the cultivation, research, production and sale of TCM. The research techniques, production capacity and market scale of Sinopharm’s TCM formula granules rank first in China.
Sinopharm also leads the way in the number of essential medicines, products “and the production capacity of propriety Chinese medicine.
With Good Agricultural and Collection Practice (GACP) bases for medicinal materials and TCM industrial parks across China, Sinopharm has developed over 700 variety of single extracts of CTM crops and nearly 800 types of patent medicines. It also owns 12 of China’s time-honored brands, 12 national intangible cultural heritage products and various exclusive medicines and well-known Chinese trademarks,” the Sinopharm official said.
Global Mission Objective
Looking ahead, Sinopharm will continue to uphold its corporate philosophy of “all for health, health for all”, practice a people-centered philosophy and serve the “Healthy China 2030 Strategy.”
“We will build a globally-competitive holistic healthcare group that will make new and greater contributions to China’s new journey toward growing into a modern socialist country in all respects,” the Sinopharm official said.
Sinopharm Visit Marks End of Journalist Exchange Program
Meanwhile, the visit to the Sinopharm headquarter marked the conclusion of international journalist exchange program activities for journalists from the Asia-Pacific region.
Journalists from other regions of the world also had their final visit to other institutions in Beijing.
The journalist exchange program will conclude with a closing ceremony on Saturday 5 July.
By DELI-SHARON OSO
In Beijing, China
